Published in Proc Natl Acad Sci U S A on January 09, 2012
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol (2012) 1.71
Chlamydophila pneumoniae infection and cardiovascular disease. N Am J Med Sci (2013) 0.95
Potential role of M. tuberculosis specific IFN-γ and IL-2 ELISPOT assays in discriminating children with active or latent tuberculosis. PLoS One (2012) 0.94
Significant association between serum interleukin-6 and Helicobacter pylori antibody levels among H. pylori-positive Japanese adults. Mediators Inflamm (2013) 0.81
Comprehensive insight into immune regulatory mechanisms and vascular wall determinants of atherogenesis - emerging perspectives of immunomodulation. Arch Med Sci (2013) 0.81
Infection of human monocytes by Chlamydia pneumoniae and Chlamydia trachomatis: an in vitro comparative study. BMC Res Notes (2014) 0.81
T lymphocyte autoreactivity in inflammatory mechanisms regulating atherosclerosis. ScientificWorldJournal (2012) 0.80
Biochemical characterization of a Pseudomonas aeruginosa phospholipase D. Biochemistry (2015) 0.78
Mechanistic differences between phenotypes of chronic lung allograft dysfunction after lung transplantation. Transpl Int (2014) 0.78
C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood. Clin Exp Immunol (2013) 0.77
Bacterial Sphingomyelinases and Phospholipases as Virulence Factors. Microbiol Mol Biol Rev (2016) 0.76
Skin CD30(+) T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease. Auto Immun Highlights (2013) 0.75
The Helicobacter cinaedi antigen CAIP participates in atherosclerotic inflammation by promoting the differentiation of macrophages in foam cells. Sci Rep (2017) 0.75
Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease. Medicine (Baltimore) (2016) 0.75
Phospholipase D from Loxosceles laeta Spider Venom Induces IL-6, IL-8, CXCL1/GRO-α, and CCL2/MCP-1 Production in Human Skin Fibroblasts and Stimulates Monocytes Migration. Toxins (Basel) (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol (2005) 27.17
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature (2007) 16.59
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 12.72
T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol (2007) 12.20
Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 11.80
Coronary plaque disruption. Circulation (1995) 8.04
Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol (2009) 5.28
Differentiation and function of Th17 T cells. Curr Opin Immunol (2007) 5.14
Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev (2000) 3.05
Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation (2009) 2.77
Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol (2000) 2.66
Borrelia burgdorferi NapA-driven Th17 cell inflammation in lyme arthritis. Arthritis Rheum (2008) 2.45
Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res (2003) 2.44
Chlamydia pneumoniae--an infectious risk factor for atherosclerosis? Nat Rev Microbiol (2004) 2.34
Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol (2008) 2.10
The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest (2006) 1.93
Different cytokine profile and antigen-specificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur J Immunol (1997) 1.86
The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (1999) 1.77
IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/- mice. J Interferon Cytokine Res (2002) 1.58
The structure of human macrophage inflammatory protein-3alpha /CCL20. Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins. J Biol Chem (2002) 1.53
The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med (1997) 1.51
Bacterial phospholipases and pathogenesis. Microbes Infect (1999) 1.49
Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest (1993) 1.40
Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation (1997) 1.39
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol (2010) 1.36
Ultrastructural analysis of developmental events in Chlamydia pneumoniae-infected cells. Infect Immun (2000) 1.34
Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis (2010) 1.26
Phospholipase D signaling: orchestration by PIP2 and small GTPases. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.09
CCL20 and β-defensin-2 induce arrest of human Th17 cells on inflamed endothelium in vitro under flow conditions. J Immunol (2010) 1.06
Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J Immunol (2005) 1.05
Silencing or permanent activation: host-cell responses in models of persistent Chlamydia pneumoniae infection. Cell Microbiol (2005) 1.03
Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood (1995) 1.00
Transcription, expression, localization and immunoreactivity of Chlamydophila pneumoniae Phospholipase D protein. Microb Pathog (2007) 0.81
Characterization of the serological response to phospholipase D protein of Chlamydophila pneumoniae in patients with acute coronary syndromes. Microbes Infect (2009) 0.80
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78
Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13
Intraflagellar transport is required for polarized recycling of the TCR/CD3 complex to the immune synapse. Nat Cell Biol (2009) 2.94
Clinical proteomics: written in blood. Nature (2003) 2.81
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74
Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59
Borrelia burgdorferi NapA-driven Th17 cell inflammation in lyme arthritis. Arthritis Rheum (2008) 2.45
Genotyping of Bacillus anthracis strains based on automated capillary 25-loci multiple locus variable-number tandem repeats analysis. BMC Microbiol (2006) 2.22
Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17
HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol Immunother (2011) 2.16
Vascular Behçet's disease: new insights in the management of thrombosis. Expert Rev Cardiovasc Ther (2013) 2.00
The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest (2006) 1.93
Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. J Exp Med (2005) 1.90
The Helicobacter pylori vacuolating toxin inhibits T cell activation by two independent mechanisms. J Exp Med (2003) 1.87
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect (2004) 1.82
Lipoprotein (a) and venous thromboembolism in adults: a meta-analysis. Am J Med (2007) 1.76
Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost (2009) 1.75
Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72
Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72
Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71
Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med (2009) 1.69
Anthrax toxins: A paradigm of bacterial immune suppression. Trends Immunol (2006) 1.67
Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63
The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63
Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol (2002) 1.61
Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol Aspects Med (2009) 1.61
Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med (2003) 1.60
What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59
Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol (2009) 1.58
Retinal vein occlusions: a review for the internist. Intern Emerg Med (2010) 1.57
Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study. Graefes Arch Clin Exp Ophthalmol (2008) 1.57
The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. J Biol Chem (2002) 1.55
Morphologic instability and cancer invasion. Clin Cancer Res (2005) 1.55
Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54
Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53
Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci (2002) 1.52
Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost (2007) 1.50
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49
Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke (2005) 1.49
Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol (2009) 1.48
Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48
Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46
Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. Blood (2010) 1.43
The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. J Leukoc Biol (2009) 1.40
Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: focus on atrial fibrillation. Blood Coagul Fibrinolysis (2005) 1.39
Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update. Intern Emerg Med (2006) 1.39
p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells. Mol Cell Biol (2004) 1.38
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36
Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35
Extensive temporally regulated reorganization of the lipid raft proteome following T-cell antigen receptor triggering. Biochem J (2003) 1.35
Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35
Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Cellular association and assembly of a multistage delivery system. Small (2010) 1.32
Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31
Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J (2005) 1.31
Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31
Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30
Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28
The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J Invest Dermatol (2007) 1.28
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27
Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25
The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cell Microbiol (2008) 1.25
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19
Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulence factors of Helicobacter pylori. Microbes Infect (2003) 1.19
Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19
Intracellular mediators of CXCR4-dependent signaling in T cells. Immunol Lett (2007) 1.19
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol (2009) 1.18
Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. Intern Emerg Med (2012) 1.18
Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med (2004) 1.17
Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16
Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16
Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16